{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:55Z","timestamp":1787009035016,"version":"build-2736575974"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maladies infectieuses \u00e9mergentes","award":["ANRS12292"],"award-info":[{"award-number":["ANRS12292"]}]},{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Increasing rifampicin dosing is considered a potent strategy for shortening TB treatment duration. Although previous data among patients with HIV\u2013TB coinfection has shown that doubling rifampicin dosing had a small effect on EFV concentrations, its effect on the pharmacokinetics (PK) of antituberculosis drugs remains lacking in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the PK of rifampicin and isoniazid with and without EFV co-administration in patients with HIV\u2013TB coinfection using two rifampicin dosing regimens (10 and 20\u2005mg\/kg\/day) and EFV dosing (600 and 800\u2005mg q24h).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ninety-seven patients were assigned to three arms in a randomized clinical trial conducted in Uganda. Plasma concentrations of rifampicin, isoniazid, and acetyl-isoniazid were measured. PK parameters were estimated, and statistical comparisons were made using geometric mean ratios, 90% CIs and the pre-set 0.80\u20131.25 interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Doubling rifampicin dosing increased its Cmax and AUClast almost 3-fold. Adding EFV decreased rifampicin AUClast by 34%\u201340%. Isoniazid AUClast was unaffected with EFV 600\u2005mg q24h but decreased with EFV 800\u2005mg q24h by 23%. EFV increased acetyl-isoniazid concentrations, suggesting enhanced acetylation activity. At 10\u2005mg\/kg of rifampicin, 88% of patients had Cmax below the therapeutic range. However, at 20\u2005mg\/kg of rifampicin, 87% of patients achieved therapeutic concentrations, ensuring effective treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study highlights the importance of adjusting rifampicin dosing to achieve therapeutic levels in patients with coinfection. Doubling rifampicin dosing in patients with HIV\u2013TB coinfection increases the percentage of patients with Cmax within the therapeutic range. Additionally, while EFV slightly affects rifampicin and isoniazid PK, these changes are not clinically significant, supporting the efficacy and safety of the combined regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf319","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:23:54Z","timestamp":1755516234000},"page":"2945-2953","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics of rifampicin and isoniazid in patients with HIV\u2013tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292\u2013RIFAVIRENZ sub-study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-9499","authenticated-orcid":false,"given":"Thibaut","family":"Gel\u00e9","sequence":"first","affiliation":[{"name":"Service de Pharmacie, AP-HP. Universit\u00e9 Paris-Saclay, H\u00f4pital Bic\u00eatre , 78 rue du G\u00e9n\u00e9ral Leclerc, 94270 Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Atwine","sequence":"additional","affiliation":[{"name":"Epicentre , PO Box 1956, Mbarara ,","place":["Uganda"]},{"name":"SRF Research and Training Centres , PO Box 422317, Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Baudin","sequence":"additional","affiliation":[{"name":"Epicentre-M\u00e9decins Sans Fronti\u00e8res , 34, avenue Jean Jaur\u00e8s, 75019 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-2645","authenticated-orcid":false,"given":"Winnie","family":"Muyindike","sequence":"additional","affiliation":[{"name":"Mbarara Regional Referral Hospital , Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Mworozi","sequence":"additional","affiliation":[{"name":"Epicentre , PO Box 1956, Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racheal","family":"Kyohairwe","sequence":"additional","affiliation":[{"name":"Epicentre , PO Box 1956, Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keneth","family":"Kananura","sequence":"additional","affiliation":[{"name":"Epicentre , PO Box 1956, Mbarara ,","place":["Uganda"]},{"name":"Mbarara Regional Referral Hospital , Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Logoose","sequence":"additional","affiliation":[{"name":"Epicentre , PO Box 1956, Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nyehangane","sequence":"additional","affiliation":[{"name":"Epicentre , PO Box 1956, Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K T","family":"Nanjebe","sequence":"additional","affiliation":[{"name":"SRF Research and Training Centres , PO Box 422317, Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Furlan","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie-Toxicologie, AP-HP. Universit\u00e9 Paris-Saclay, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[{"name":"Immunologie des Maladies Virales, Auto-immunes, H\u00e9matologiques et Bact\u00e9riennes, Universit\u00e9 Paris-Saclay, Inserm, CEA , 92265 Fontenay-aux-Roses ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-7393","authenticated-orcid":false,"given":"Maryline","family":"Bonnet","sequence":"additional","affiliation":[{"name":"TransVIHMI, University of Montpellier, IRD\/INSERM , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-6275","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Barrail-Tran","sequence":"additional","affiliation":[{"name":"Service de Pharmacie, AP-HP. Universit\u00e9 Paris-Saclay, H\u00f4pital Bic\u00eatre , 78 rue du G\u00e9n\u00e9ral Leclerc, 94270 Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Immunologie des Maladies Virales, Auto-immunes, H\u00e9matologiques et Bact\u00e9riennes, Universit\u00e9 Paris-Saclay, Inserm, CEA , 92265 Fontenay-aux-Roses ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ANRS12292 Rifavirenz study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L-A","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jindani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Justumus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Mendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Muzanye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Falissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2025110817242557600_dkaf319-B1","volume-title":"Global Tuberculosis Report 2023","author":"World Health Organization","year":"2023"},{"key":"2025110817242557600_dkaf319-B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2025110817242557600_dkaf319-B3","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"Steingart","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025110817242557600_dkaf319-B4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.5588\/ijtld.15.0577","article-title":"A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis","volume":"20","author":"Jindani","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025110817242557600_dkaf319-B5","doi-asserted-by":"publisher","first-page":"e01054-17","DOI":"10.1128\/AAC.01054-17","article-title":"Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis","volume":"61","author":"Aarnoutse","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025110817242557600_dkaf319-B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciy026","article-title":"The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis","volume":"67","author":"Svensson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025110817242557600_dkaf319-B8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial","volume":"198","author":"Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110817242557600_dkaf319-B9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/0003-4819-127-4-199708150-00006","article-title":"Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection","volume":"127","author":"Sahai","year":"1997","journal-title":"Ann Intern Med"},{"key":"2025110817242557600_dkaf319-B10","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1128\/AAC.48.11.4473-4475.2004","article-title":"Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease","volume":"48","author":"Gurumurthy","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","article-title":"Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients","volume":"50","author":"McIlleron","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025110817242557600_dkaf319-B13","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1128\/aac.05526-11","article-title":"Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines","volume":"56","author":"McIlleron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B14","first-page":"70","article-title":"Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers","volume":"5","author":"Pargal","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025110817242557600_dkaf319-B15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis","volume":"58","author":"Abulfathi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2025110817242557600_dkaf319-B16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/jac\/dkz557","article-title":"Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial","volume":"75","author":"Atwine","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025110817242557600_dkaf319-B17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/004982597239994","article-title":"Rifampin and rifabutin and their metabolism by human liver esterases","volume":"27","author":"Jamis-Dow","year":"1997","journal-title":"Xenobiotica"},{"key":"2025110817242557600_dkaf319-B18","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1073\/pnas.93.9.4001","article-title":"P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans","volume":"93","author":"Schuetz","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025110817242557600_dkaf319-B19","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"54","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B20","doi-asserted-by":"publisher","first-page":"1441147","DOI":"10.3389\/fphar.2024.1441147","article-title":"Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement","volume":"15","author":"Sankar","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025110817242557600_dkaf319-B21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/bcp.13600","article-title":"Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: a systematic review","volume":"84","author":"Atwine","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025110817242557600_dkaf319-B22","volume-title":"Treatment of Tuberculosis: Guidelines","author":"World Health Organization","year":"2010"},{"key":"2025110817242557600_dkaf319-B23","first-page":"80","volume-title":"Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care","author":"World Health Organization","year":"2017"},{"key":"2025110817242557600_dkaf319-B24","first-page":"231","article-title":"A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine","volume":"36","author":"Hemanth Kumar","year":"2004","journal-title":"Indian J Pharmacol"},{"key":"2025110817242557600_dkaf319-B25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0b013e31826ebb5c","article-title":"Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers","volume":"61","author":"Huang","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025110817242557600_dkaf319-B26","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1128\/aac.02379-13","article-title":"Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment","volume":"58","author":"Bhatt","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/jac\/dku348","article-title":"Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship","volume":"70","author":"Bhatt","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025110817242557600_dkaf319-B28","author":"Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)"},{"key":"2025110817242557600_dkaf319-B29","doi-asserted-by":"publisher","first-page":"11438","DOI":"10.1038\/s41598-023-38716-3","article-title":"Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in Ethiopian tuberculosis patients","volume":"13","author":"Sileshi","year":"2023","journal-title":"Sci Rep"},{"key":"2025110817242557600_dkaf319-B30","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJM199212173272514","article-title":"Malabsorption of antituberculosis medications by a patient with AIDS","volume":"327","author":"Berning","year":"1992","journal-title":"N Engl J Med"},{"key":"2025110817242557600_dkaf319-B31","volume-title":"European AIDS Clinical Society Guidelines v12.1","author":"European AIDS Clinical Society","year":"2024"},{"key":"2025110817242557600_dkaf319-B32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral society\u2013USA panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"2025110817242557600_dkaf319-B33","first-page":"592","volume-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach","author":"World Health Organization","year":"2021"},{"key":"2025110817242557600_dkaf319-B34","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/cpt.778","article-title":"A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses","volume":"103","author":"Svensson","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025110817242557600_dkaf319-B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/AAC.01830-15","article-title":"Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction","volume":"60","author":"Chirehwa","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817242557600_dkaf319-B37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1254\/jphs.08209fp","article-title":"Induction of multiple drug transporters by efavirenz","volume":"109","author":"Weiss","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"2025110817242557600_dkaf319-B38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/clpt.2011.255","article-title":"Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers","volume":"91","author":"Oswald","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2025110817242557600_dkaf319-B39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1124\/dmd.119.089052","article-title":"Influence of UGT1A1 and SLCO1B1 polymorphisms and efavirenz on bilirubin disposition in healthy volunteers","volume":"48","author":"Collins","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"2025110817242557600_dkaf319-B40","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/jac\/dkab258","article-title":"Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV","volume":"76","author":"Sundell","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025110817242557600_dkaf319-B41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/jac\/dky378","article-title":"Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid","volume":"74","author":"Chirehwa","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025110817242557600_dkaf319-B42","volume-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment","author":"World Health Organization","year":"2022"},{"key":"2025110817242557600_dkaf319-B43","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1128\/aac.02599-12","article-title":"Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients","volume":"57","author":"Tostmann","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/2945\/64161709\/dkaf319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/2945\/64161709\/dkaf319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:24:37Z","timestamp":1762640677000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/11\/2945\/8244077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf319","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,29]]}}}